The Pasteur Institute of Ivory Coast and Millenia Hope Biopharma Sign an Important Collaboration Agreement

Share Article

L’Institut Pasteur de Côte d’Ivoire et Millenia Hope Biopharma signent une importante entente de collaboration.

The Pasteur Institute of Ivory Coast (PIIC), represented by its Director, Professor Mireille Dosso, has the pleasure to announce that it has concluded a scientific and technical collaboration agreement with Millenia Hope Biopharma, a subsidiary of Millenia Hope Inc.(NASDAQ-OTC:BB-MLHP FRANKFURT – MLF)

In order to achieve the objective of the eradication of infectious diseases, in particular malaria and [HIV], objectives that were established by the Ivory Coast Ministry of Health and Public Hygiene as well as its Ministry of Superior Teaching and Scientific Research, the PIIC has joined this collaboration with Millenia Hope Biopharma to allow it to reinforce its support for the public health policies of the Ivory Coast.

Millenia Hope Biopharma is very aware of the international reputation of PIIC and has committed itself to the vigilance and scientific expertise of the Pasteur Institute, in the context of its activities in the Ivory Coast.

Leonard Stella, Chairman and CEO of Millenia Hope Biopharma and Millenia Hope Inc, stated, ‘Collaborating with such a prestigious and dedicated organization, as the Pasteur Institute, will surely aid in the fight against these ravaging diseases and, we pray, will allow our efforts to help alleviate the suffering in the Ivory Coast and worldwide’.

Version Francais

L’Institut Pasteur de Côte d’Ivoire, représenté par son Directeur Madame le Professeur Mireille DOSSO, a le plaisir d’annoncer que cette institution a conclu ce jour, une entente de collaboration scientifique et technique avec la société Millenia Hope Biopharma.

Aux fins d’atteindre les objectifs d’éradication des maladies infectieuses notamment le paludisme et le VIH, fixés par le Ministère de la santé et de l’hygiène publique ainsi que le Minisère de l’enseignement Supérieur et de la Recherche Scientifique, l’IPCI espère que cette collaboration avec Millenia Hope Biopharma lui permettra de renforcer son appui à la politique de santé publique de Côte d’Ivoire.

De son côté, Millenia Hope Biopharma conscient de la renommée internationale de l’IPCI se soumet à la vigilance et à l’expertise scientifique de cette institution dans le cadre de l’installation de ses activités en Côte d’Ivoire.

About Millenia Hope Biopharma

Millenia Hope Biopharma (MHB) is one of the world’s leading bioresearch firms in Phytomic Technologies, commercializing plant-cell based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. MHB has spent over $30 million in developing its unique Phytomics Technologies, including the world’s largest library of highly purified phytochemical fractions to be utilized by the pharmaceutical, cosmetic and nutraceutical industry. MHB is in the midst of the commercializing several projects with leading multi-national corporations.

About Millenia Hope

Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

About Institut Pasteur

Institut Pasteur is a non-profit private foundation which contributes to the prevention and treatment of disease, primarily infectious diseases, through research, education, and public health activities.

Safe Habor Statement:

Certain statements made in the release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as ‘forward-looking statements’. Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.

For more information:

Please contact: Mr. Leonard Stella, Chairman & CEO

Tel: (514) 846-5757 or (514) 288-8822

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Leonard Stella
Visit website